Strategic partnerships Target collaborations with large biopharma CRO networks and AI-driven drug discovery platforms, leveraging Eurofins DiscoveryOne capabilities and Beacondiscovery acquisition to offer integrated discovery services and expanded computational chemistry support.

AI and NAMs Position DiscoveryAI SAFIRE and NAM-focused approaches as a differentiator to win clients seeking in silico ADMET refinement and accelerated lead optimization, especially for partners with advanced computational needs.

Expansion opportunities Leverage recent collaborations and client wins to pursue cross-sell with Dompé farmaceutici and Awakn Life Sciences, offering comprehensive organic synthesis libraries, medicinal chemistry, and early pharmacology services.

Portfolio leverage Highlight unique organic molecule collections and patentable structures to biotech startups and emerging pharma players looking for novel lead candidates and accelerated discovery timelines.

Global reach Emphasize Eurofins network credibility and integrated services to attract multinational clients seeking a one-stop CRO for discovery, synthesis, ADMET, and AI-enabled evaluation across regions.